Drug Profile
Rongliflozin - HEC Pharm
Alternative Names: 14C-Rongliflozin; HEC-44616Latest Information Update: 26 Aug 2022
Price :
$50
*
At a glance
- Originator HEC Pharm
- Developer Sunshine Lake Pharma
- Class Antihyperglycaemics
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 18 Aug 2022 Sunshine Lake Pharma completes a phase I trial in Type 2 diabetes mellitus (In volunteers) in China (PO)(NCT05497674)
- 18 May 2022 Phase I development is ongoing for in Type 2 diabetes mellitus in China (PO) (NCT05374343)
- 05 May 2022 Phase-I clinical trials in Type 2 diabetes mellitus in China (PO) (NCT05374343)